New considerations in infectious disease outbreaks: The threat of genetically modified microbes

Clinical Infectious Diseases

Volumn 40, Issue 8, 2005, Pages 1160-1165

  Gilsdorf, Janet R ^a,b   Zilinskas, Raymond A ^a  

^a MONTEREY INSTITUTE OF INTERNATIONAL STUDIES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE;

BACTERIAL INFECTION; BACTERIUM DETECTION; BIOENGINEERING; BIOLOGICAL WARFARE; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE TRANSMISSION; DNA MODIFICATION; EPIDEMIC; EPIDEMIOLOGICAL DATA; GENE INSERTION; GENETIC CODE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFECTION RATE; LABORATORY DIAGNOSIS; MICROORGANISM; PNEUMONIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RECOMBINANT GENE; REVIEW; TREATMENT FAILURE; VACCINATION; VIRUS DETECTION; VIRUS INFECTION;

BACTERIAL INFECTIONS; DISEASE OUTBREAKS; HUMANS; ORGANISMS, GENETICALLY MODIFIED; VIRUS DISEASES;

EID: 16844382461     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428843     Document Type: Review

References (60)

1. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA 1997; 278:418-24.
2. Zilinskas RA, Tucker JB. Open scientific publications as a possible source of know-how for biological terrorism and warfare. J Homeland Security, 20 December 2002. Available at: http://www.homelandsecurity.org/journal/ArticIes/ tucker.html. Accessed on 3 March 2005.
3. Caudle LC. The biological warfare threat. In: Zajtchuk R, ed. Textbook of military medicine. Washington, DC: Office of The Surgeon General, Department of the Army, 1997:451-66.
4. Alibek K, Handleman S. Biohazard: the chilling true story of the largest covert biological weapons program in the world - told from inside by the man who ran it. New York: Random House, 1999.
5. Popov, S. Interview - Serguei Popov, 1 November 2000. J Homeland Security, 13 November 2000. Available at: http://www.homelandsecurity.org/ journal/Interviews/PopovInterview_001107.htm. Accessed on 3 March 2005.
6. National Research Council. Biotechnology research in an age of terrorism. Washington, DC: The National Academies Press, 2004.
7. Cheshenko NV, Petrov VS, Protopopova EV, et al. Recombinant vaccinia virus expressing Japanese encephalitis virus protein E [in Russian]. Mol Gen Mikrobiol Virusol 1997; (3):24-7.
8. Netesova NA, Petrova VS, Cheshenko NV, Chikaev NA, Malygin EG, Mertvetsov NP. Expression of a synthetic gene for human angiogenin in a recombinant vaccinia virus [in Russian]. Bioorg Khim 1995; 21:608-11.
9. Sviatchenko VA, Kiselev NN, Ryzhikov AB, Bulychev LE, Mikriukova TP, Netesov SV. Immunogenicity of recombinant vaccinia virus strain (VR26) expressing Venezuelan equine encephalomyelitis (VEE) virus structural protein genes was studied by oral immunization [in Russian]. Vopr Virusol 2000; 45:38-41.
10. Chepurnov AA, Ternovo VA, Dadaeva AA, et al. Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus [in Russian]. Vopr Virusol 1997; 42:115-20.
11. Serpinski OI, Kochneva GV, Urmanov IK, Sivolobova GF, Riabchikova EI. Construction of recombinant variants or orthopoxviruses by inserting foreign genes into intragenic region of viral genome [in Russian]. Mol Biol (Mosk) 1996; 30:1055-65.
12. Goncharova EP, Ryzhikov AB, Bulychev LE, et al. A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus. Wien Klin Wochenschr 2002; 114:630-5.
13. Sviatchenko VA, Agapov EV, Urmanov IK, et al. The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus [in Russian]. Vopr Virusol 1993; 38:222-6.
14. Kolesnikova L, Muhlberger E, Ryabchikova E, Becker S. Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions. J Virol 2000; 74:3899-904.
15. Ryzhikov AB, Goncharova EP, Bulychev LE, et al. Studying the possibility of respiratory immunization against tick-borne encephalitis [in Russian]. Vestn Ross Akad Med Nauk 1998; 4:17-20.
16. Khromykh AA, Beliaev AS, Rukavishnikov MI, Daniliuk NK, Sandakhchiev LS. Expression of antigens of the tick-borne encephalitis virus by various recombinant variants of the vaccinia virus [in Russian]. Dokl Akad Nauk SSSR 1990; 310:996-9.
17. Shchelkunov SN, Stavitskii SB, Batenko LI, et al. Viral chimeric protein including a determinant of myelin basic protein is capable of inducing allergic encephalomyelitis in guinea pigs. Biomed Sci 1991; 2:493-7.
18. Tat'kov SI, Sivolobova GF, Kochneva GV, Reshetnikov SS, Tsivkovskaia RI, Serpinski OI. Expression of a hybrid protein between human gamma-interferon and alpha-fetoprotein in E. coli cells [in Russian]. Mol Biol (Mosk) 1996; 30:1299-306.
19. Petrenko VA, Tat'kov SI, Eroshkin AM, Boldyrev AN, Pozdniakov PI. Primary structure of the mutant genes of human leukocyte interferon alpha2 [in Russian]. Bioorg Khim 1988; 14:810-4.
20. Seregin SV, Siniakov AN, Pozdniakov SG, Sakhno LV, Leplina OI, Nomokonova NI. Preparation of hybrid proteins consisting of human interleukin-2 and the cytotoxic A-subunit of Shigella toxin [in Russian]. Mol Biol (Mosk) 1993; 27:763-72.
21. Seregin SV, Riabinin VA, Siniakov AN, Daniliuk NK, Pozdniakov SG. Reconstruction of the synthetic gene for human interleukin-2 [in Russian]. Bioorg Khim 1990; 16:759-64.
22. Korepanova AV, Eroshkin AM, Ivanisenko VA, et al. Preparation of a mutant human tumor necrosis factor with increased resistance to proteases [in Russian]. Mol Biol (Mosk) 1994;28:143-9.
23. Korobko VG, Davydov IV, Dobrynin VN, et al. Preparation and bacterial expression of a mutant gene for human lymphotoxin [in Russian]. Bioorg Khim 1993; 19:414-9.
24. Masycheva VI, Fadina VA, Danilenko ED, et al. The immunoregulatory properties of recombinant human tumor necrosis factor-beta in mice opposite-reacting to antigen [in Russian]. Eksp Klin Farmakol 1999; 62:44-7.
25. Masycheva VI, Danilenko ED, Morozova EN, et al. Toxic properties of recombinant tumor necrosis factor [in Russian]. Antibiot Khimioter 1997; 42:24-7.
26. Lebedev LR, Pustoshilova NM, Sinichkina SA, Andreeva IS. Preparation of lymphotoxin and properties of it [in Russian]. Prikl Biokhim Mikrobiol 1998; 34:120-6.
27. Sandakhchiev LS, Merzlikin NV, Pustoshilova NM, et al. Certain biological properties of mutant human tumor necrosis factor-alpha [in Russian]. Biull Eksp Biol Med 1998; 125:89-92.
28. Il'ichev AA, Minenkova OO, Belikov SI, Timofeev IV, Pugachev VG. Expression of the artificial gene for human leukocyte interferon alpha 2 cloned in phage M13MP8 [in Russian]. Mol Gen Mikrobiol Virusol 1986; 8:19-23.
29. Il'ichev AA, Belikov SI, Pugachev VG, Timofeev IV, Zorin VV. Design of a recombinant plasmid allowing the selection of an optimal promoter for the human interferon alpha2 gene [in Russian]. Mol Gen Mikrobiol Virusol 1986; 7:23-6.
30. Akimenko ZA, Zykov SA, Shaprov W, et al. A chemically synthesized gene assures the biosynthesis of a polypeptide in Escherichia coli cells, the structure of which corresponds to human leukocytic interferon alpha 2 [in Russian]. Dokl Akad Nauk SSSR 1991; 319:1248-51.
31. Kravchenko VV, Gileva IP, Shamin VV, Kulichkov VA, Dobrynin VN. Duplication of a synthetic gene for human leukocyte interferon and its expression in polycistron mRNA with coupled translation system [in Russian]. Bioorg Khim 1987; 13:1186-93.
32. Petrenko LA, Gileva IP, Kravchenko VV. Construction and properties of the expression vector based on the temperature-regulated P'R promoter in phage lambda DNA [in Russian]. Bioorg Khim 1987; 13:1561-9.
33. Korobko VG, Boldyreva EF, Filippov SA, et al. Synthesis of an artificial gene coding for thymosin alpha1 and its expression in Escherichia coli as a hybrid with human tumor necrosis factor [in Russian]. Bioorg Khim 1992; 18:646-59.
34. Korobko VG, Davydov IV, Shingarova LN, et al. Hybrid human lymphokine genes. I. Design of recombinant plasmids coding hybrids of immune interferon and human tumor necrosis factor [in Russian]. Bioorg Khim 1991; 17:189-96.
35. Nikonova AA, Seregin SV, Chikaev NA, Mishin VP, Babkina IN, Mertvetsov NP. Expression of synthetic gene for human angiogenin in E. coli cells [in Russian]. Bioorg Khim 1996; 22:891-3.
36. Kovalenko SP, Lisnyak IA, Mertvetsov NP. Expression of synthetic human angiogenin gene in E. coli in cleaved beta-galactosidase-angiogenin protein [in Russian]. Bioorg Khim 1989; 15:492-8.
37. Babkina IN, Seregin SV, Daniliuk NK, Siniakov AN, Gladkova SE, Pozdniakov SG. Chemico-enzymatic synthesis, cloning and expression of a gene for an analog of human anaphylatoxin C5a [in Russian]. Bioorg Khim 1995; 21:359-64.
38. Kuvshinov VN, Kuz'micheva GA, Masycheva VI, et al. Ability of a recombinant protein containing fragment 114-122 of myelin basic protein, to cause allergic encephalomyelitis in guinea pigs [in Russian]. Mol Gen Mikrobiol Virusol 1996; 2:18-22.
39. Petrenko VA, Il'ichev AA, Bedristov AI, et al. The structural determinants of the myelin basic protein that define sensitivity to viral infections: the cloning and determination of the primary mRNA structure of the myelin basic protein in adults [in Russian]. Dokl Akad Nauk SSSR 1990; 313:494-7.
40. Tikunova NV, Golovin SI, Mikriukov NN, et al. Synthesis, cloning and determination of the primary structure of human alpha 1-antitrypsin cDNA [in Russian]. Bioorg Khim 1991; 17:1694-7.
41. Tikunova NV, Golovin SI, Mikriukov NN, Il'ichev AA. Synthesis, cloning, and expression in Escherichia coli cells of human alpha1-antitrypsin cDNA [in Russian]. Mol Gen Mikrobiol Virusol 1996; 3:36-40.
42. Panin LE, Maksiutov AZ, Poteriaeva ON, Poliakov LM. Immunochemical identification of the suggested receptor domain for human insulin [in Russian]. Dokl Akad Nauk 1996; 349:262-4.
43. Beklemishev AB, Golovin SI, Il'ichev AA, Mamaev LV, Krasnykh VN. Expression in Escherichia coli cells of the nucleotide sequence of DNA coding for the bovine lipotropic hormone [in Russian]. Mol Gen Mikrobiol Virusol 1987; 10:19-23.
44. Golovin SI, Bondar AA, Karginov VA, Morozov IV, Zelenin SM. Synthesis, cloning and primary structure of cDNA for proopiomelanocortin from the pituitary gland of the mink (Mustella vison) [in Russian]. Bioorg Khim 1988; 14:273-5.
45. Golovin SI, Karginov VA, Bondar AA, Beklemishev AB, Chekhranova MK. Synthesis, cloning and primary structure of DNA complementary to mRNA for human pituitary pro-opiomelanocortin [in Russian]. Bioorg Khim 1987; 13:562-4.
46. Mertvetsov NP, Golovin SI, Beklemishev AB, Karginov VA, Mamaev LV. Cloning of DNA complementary to mRNA for proopiomelanocortin from the bovine, rat and human hypophysis: hormonal regulation of proopiomelanocortin mRNA in the rat hypophysis [in Russian]. Biokhimiia 1987; 52:707-14.
47. Khlebodarova TM, Karasik GI, Matveeva NM, et al. The mink proopiomelanocortin gene: characterization of cDNA and chromosomal localization. Genomics 1988; 2:185-8.
48. Dobrynin VN, Boldyreva EF, Filippov SA, Chuvpilo SA, Korobko VG. The vector containing a signal for specific degradation of chimeric proteins: synthesis of [Leu5]enkephalin using enteropeptidase [in Russian]. Bioorg Khim 1987; 13:119-21.
49. Dertzbaugh MT. Genetically engineered vaccines, an overview. Plasmid 1998; 39:100-13.
50. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93:11341-8.
51. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002; 8:225-30.
52. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-31.
53. Centers for Disease Control and Prevention. Pneumocystis pneumonia - Los Angeles. MMWR 1981; 30:1-3.
54. Centers for Disease Control and Prevention. Outbreak of West Nile-like viral encephalitis - New York, 1999. MMWR 1999; 48:845-9.
55. Bush LM, Abrams BH, Beall A, Johnson CC. Brief report: index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345:1607-10.
56. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004; 350:342-50.
57. Pomerantsev AP, Staritsin NA, Mockov Y, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997; 15:1846-50.
58. Jackson RJ, Ramsay AJ, Christianson CD, Beaton S, Hall D, Ramshaw I. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75:1205-10.
59. Meyer K. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970; 42:653-66.
60. Heath DG, Anderson GW Jr, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998; 16:1131-7.